Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0461929603
Mon, 22.08.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Intron Health initiates research coverage of Xlife Sciences
22.08.2022 / 07:00 CET/CEST
Intron Health today published its first independent research report on Xlife Sciences (SIX: XLS). The coverage starts with a «Buy» rating and a target price of CHF 47. Intron Health has evaluated [ … ]
Mon, 22.08.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Intron Health initiates research coverage of Xlife Sciences
22.08.2022 / 07:00 CET/CEST
Intron Health today published its first independent research report on Xlife Sciences (SIX: XLS). The coverage starts with a «Buy» rating and a target price of CHF 47. Intron Health has evaluated [ … ]
Mon, 04.07.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
FUSE-AI supports German pharmacies in digitization
04.07.2022 / 07:01
Xlife Sciences’ (SIX: XLS) project company FUSE-AI has been appointed as strategic partner in the field of digitization by the pharmacy associations and federations of all 16 German federal states. FUSE-AI and the [ … ]
Mon, 04.07.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
FUSE-AI supports German pharmacies in digitization
04.07.2022 / 07:01
Xlife Sciences’ (SIX: XLS) project company FUSE-AI has been appointed as strategic partner in the field of digitization by the pharmacy associations and federations of all 16 German federal states. FUSE-AI and the [ … ]
Mon, 16.05.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Project company Xsight Optics successfully participates in start-up competition – prize money finances relevant R&D project
16.05.2022 / 07:05
Xsight Optics, based in Jena (Germany), a project company of Xlife Sciences AG (SIX: XLS), has successfully participated in this year's [ … ]
Mon, 09.05.2022
Xlife Sciences AG
Xlife Sciences AG (SIX: XLS) today for the first time published an independent assessment of its project portfolio and intends to issue this report annually from now on.
The extensive Valuation Report as of December 31, 2021 identified a valuation range of CHF 574 million up to CHF 701 million. The average value of this range corresponds to more t [ … ]
Fri, 29.04.2022
Xlife Sciences AG
Highlights 2021:
Successful exit of a project company through the initial public offering of Vitruvia Medical on the Stock Exchange in Munich (unregulated market ['Freiverkehr']. Vitruvia Medical develops innovative circulatory systems for very complex medical devices, in particular robot-assisted surgery. Around 60 percent of the ongoing projec [ … ]
Mon, 25.04.2022
Xlife Sciences AG
Xlife Sciences AG (SIX: XLS) today announced that its project company Baliopharm has achieved an important R&D milestone in the development of the product candidate ATROSIMAB for the treatment of Non-alcoholic steatohepatitis (NASH) and potentially other chronic liver diseases. The phase 1 of the in-vivo trial evaluating the safety, tolerabili [ … ]
Thu, 21.04.2022
Xlife Sciences AG
Xlife Sciences AG (SIX: XLS) today announced that due to the change from the Munich Stock Exchange (unregulated market ['Freiverkehr'] to the regulated market of the SIX Swiss Exchange (SME Segment 'Sparks') and the related change of auditors, the company will publish its annual report 2021 newly on 29 April 2022.
Financial calendar
Annual Report [ … ]
Fri, 11.02.2022
Xlife Sciences AG
Media Release
Zurich, February 11, 2022, 7 am CET
Xlife Sciences' shares begin trading on SIX Swiss Exchange
- As of 3 pm CET today, the shares of Xlife Sciences AG will be traded on SIX Swiss Exchange - as the first company in the new "Sparks" segment.
- The reference price is CHF 44.71 and corresponds to the closing price of EUR 42.20 at the [ … ]